This article needs to be updated. Please help update this article to reflect recent events or newly available information. (October 2021)

rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a prospective vaccine against tuberculosis created by a team headed by Marcus A. Horwitz at UCLA. It is a live vaccine, consisting of BCG genetically modified to produce abundant amounts of a 30kDa antigen (Antigen 85B) that has been shown to produce a strong immune response in animals[1][2][3][4] and humans. The vaccine completed a Phase I double-blind randomized controlled clinical trial that demonstrated that rBCG30 was safe and immunogenic; during nine months of follow-up, rBCG30, but not BCG, induced significantly increased Antigen 85B-specific immune responses in eight immunological assays (blood lymphocyte proliferation, antibody responses by ELISA, interferon-gamma producing CD4+ and CD8+ T cells ex vivo, central memory CD4+ and CD8+ T cells, interferon-gamma ELISPOT responses, and the capacity of T cells to activate macrophages to inhibit mycobacterial intracellular multiplication).[5]

References

  1. ^ Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S (December 2000). "Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model". Proc. Natl. Acad. Sci. U.S.A. 97 (25): 13853–8. Bibcode:2000PNAS...9713853H. doi:10.1073/pnas.250480397. PMC 17665. PMID 11095745.
  2. ^ Horwitz MA, Harth G (April 2003). "A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis". Infect. Immun. 71 (4): 1672–9. doi:10.1128/iai.71.4.1672-1679.2003. PMC 152073. PMID 12654780.
  3. ^ Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S (January 2006). "Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity" (PDF). Vaccine. 24 (4): 443–51. doi:10.1016/j.vaccine.2005.08.001. PMID 16125825. S2CID 8581702.
  4. ^ Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S (March 2006). "A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG" (PDF). Vaccine. 24 (10): 1593–600. doi:10.1016/j.vaccine.2005.10.002. PMID 16257099. S2CID 11798572.
  5. ^ Hoft DF, Blazevic A, Abate G, et al. (November 2008). "A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers". J. Infect. Dis. 198 (10): 1491–501. doi:10.1086/592450. PMC 2670060. PMID 18808333.


Categories